We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Refiles NDA for Btripla HIV Single-Tablet Regimen
Gilead Refiles NDA for Btripla HIV Single-Tablet Regimen
February 11, 2011
Gilead has refiled its NDA for Btripla, a single-tablet HIV treatment for adults that combines Truvada and Tibotec Pharmaceutical’s non-nucleoside reverse transcriptase inhibitor TMC278.